Harrow(NASDAQ) HROWL

Market CapN/A

Since IPO (2021)+45%

5 YearN/A

1 Year+9%

1 Month-0%

$0.00

+0%

+0.00Today

Harrow last closing stock price
Metric	Price	Date
Last close	USD 25.61	2025-10-10

Harrow stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-0.16%	USD 25.65	2025-10-03
1 month	-0.12%	USD 25.64	2025-09-10
3 month	+2.22%	USD 25.05	2025-07-11
Year to date	+8.01%	USD 23.71	2024-12-31
1 year	+8.89%	USD 23.52	2024-10-10
3 year	+38.41%	USD 18.50	2022-10-11
Since inception	+45.46%	USD 17.61	2021-05-07

Harrow Financials at a Glance

Market Cap

N/A

Revenue (TTM)

$268.68M

Net Income (TTM)

-$14.96M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

$0.00

Volume

N/A

Open

N/A

Price

$0.00

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 17, 2025

Dividend

N/A

Beta (Volatility)

N/A

Price

$0.00

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 17, 2025

HROWL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Harrow

Harrow Health, Inc. is a pharmaceutical company focused on developing, producing, and distributing innovative medications. The company operates primarily in two segments: Pharmaceutical Compounding and Pharmaceutical Drug Development, with a notable presence through its ImprimisRx business.

Products and Services

Pharmaceutical Compounding services tailored to patient-specific needs
Innovative drug development aimed at addressing unmet medical needs
Specialty medications for various therapeutic areas

Growth Outlook

Recent revenue of $44.2 million in Q1 2026 indicates potential for growth
Trailing twelve months (TTM) gross profit margin of 74.1% reflects strong operational efficiency
Current ratio of 2.48 suggests solid liquidity position for future investments

Financial Highlights

Net income of -$27.6 million in Q1 2026 shows challenges in profitability
Operating income margin of -49.9% in Q1 2026 highlights operational hurdles
Cash and cash equivalents of $94.6 million as of March 31, 2026, provide financial stability

Harrow Health, Inc. has established itself as a key player in the pharmaceutical industry, particularly through its focus on personalized medicine and innovative drug solutions. The company's recent financial performance indicates both challenges and opportunities. While the net income reflects ongoing operational difficulties, the strong gross profit margin and liquidity position suggest that Harrow Health is well-positioned to navigate its current landscape. The company's commitment to developing specialized medications may drive future growth, making it an intriguing option for investors interested in the healthcare sector.

AI Generated • Jul 14, 2026

Industry

Pharmaceuticals

Sector

Health Care

Headquarters

Nashville, DE, US

HROWL Financials

Key Financial Metrics (TTM)

Gross Margin

74.11%

Operating Margin

10.47%

Net Income Margin

-5.57%

Return on Equity

-33.65%

Return on Capital

12.68%

Return on Assets

-3.57%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/A

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$199.11M

Operating Income

$28.12M

EBITDA

$31.47M

Operating Cash Flow

$15.20M

Capital Expenditure

-$926.00K

Free Cash Flow

$14.28M

Cash & ST Invst.

$94.64M

Total Debt

$300.67M

Harrow Performance Analysis

Harrow sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	33.3%
Q3	2025-09-30	12.4%
Q4	2025-12-31	24.4%
Q1	2026-03-31	-50.4%

Harrow sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	126.0%
Q3	2025-09-30	-79.8%
Q4	2025-12-31	587.0%
Q1	2026-03-31	-511.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$44.20M

-7.6%

Gross Profit

$27.05M

-16.3%

Gross Margin

61.18%

N/A

Market Cap

N/A

Market Cap/Employee

N/A

Employees

217

N/A

Net Income

-$27.60M

-55.2%

EBITDA

-$16.50M

-146.4%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$94.64M

+41.8%

Total Debt

$300.67M

+30.7%

Accounts Receivable

$101.26M

+31.0%

Inventory

$16.50M

+53.9%

Long Term Debt

$299.75M

+147.6%

Short Term Debt

$915.00K

-99.2%

Return on Assets

-3.57%

N/A

Return on Invested Capital

8.57%

N/A

Free Cash Flow

-$9.19M

-147.2%

Operating Cash Flow

-$8.99M

-145.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

AGTIAgiliti, Inc.

AGTIAgiliti, Inc.$10.05-0.50%

HSKAHeska Corporation

HSKAHeska Corporation$119.99+0.00%

PNTPOINT Biopharma Global Inc.

PNTPOINT Biopharma Global Inc.$12.50+0.16%

VIVOVivoPower PLC

VIVOVivoPower PLC$3.92-8.31%

BKDBrookdale Senior Living Inc.

BKDBrookdale Senior Living Inc.$15.47+2.11%

CINCCinCor Pharma, Inc.

CINCCinCor Pharma, Inc.$29.06+0.00%

SILKSilk Road Medical, Inc

SILKSilk Road Medical, Inc$27.49-0.04%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF

NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF$5.25+0.10%

NOKNokia

NOKNokia$9.28+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$14.95+0.03%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.24-0.02%

TAT&T

TAT&T$24.42+0.01%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$63.40-0.01%

ONDSOndas

ONDSOndas$8.02+0.03%

Questions About HROWL

What is the current price of Harrow?

Harrow is trading at N/A per share.

What is the 52-week range for Harrow?

Over the past 52 weeks, Harrow has traded between N/A and N/A.

How much debt does Harrow have?

Harrow total debt is unavailable.

How much cash does Harrow have on hand?

Harrow does not have cash on hand data available.

What is Harrow’s dividend yield?

Harrow does not currently have a dividend yield.

Harrow(NASDAQ) HROWL

Harrow Financials at a Glance

HROWL News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Harrow

HROWL Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Harrow Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About HROWL

What is the current price of Harrow?

What is the 52-week range for Harrow?

How much debt does Harrow have?

How much cash does Harrow have on hand?

What is Harrow’s dividend yield?

Premium Investing Services